September 21, 2022
Research Report
Independent analysis
Report ID: 25230

noble

Baudax Bio Inc. (BXRX) - Curing a Deficiency


Gregory AurandMedia Inquiries
Senior Healthcare Services & Medical Devices Analyst
0 min read
Get a Report
Refer to the full report for the price target, fundamental analysis, and rating.

The Company in this report is a participant in the Company Sponsored Research Program (“CSRP”); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.

The Company has attended Noble investor conference(s) in the last 12 months.

Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.


Baudax Bio Inc.
Baudax Bio Inc.
Healthcare
Biotechnology
Ticker
BXRX
Current Price
$0.2459 6.77%
Market Cap
$2.0M
Price Target
Refer to Report
Volume
668.0K
52wk Range
$0.22 - $22.4
Related Research Reports
9/21/2022

Curing a Deficiency
Curing a Deficiency (BXRX)
8/31/2022

Priced Common Offering; Reducing Price Target
Priced Common Offering; Reducing Price Target (BXRX)
8/23/2022

Notice of Patent Allowance For Claims Covering ANJESO
Notice of Patent Allowance For Claims Covering ANJESO (BXRX)
8/12/2022

Baudax Bio reports 2Q 2022; Headwinds Persist
Baudax Bio reports 2Q 2022; Headwinds Persist (BXRX)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.